Stella Chemifa Of Japan To Commercialize Boron Isotope Cancer Treatment System
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Stella Chemifa plans to commercialize its boron neutron capture treatment by 2011. BNCT uses neutron rays to radiate cancer tissues embedded with boron isotope chemical, and selectively kill cancer cells. By only destroying targeted cells and having no impact to other cells, BNCT can be used to treat malignant cancers such as brain tumors, mesothelioma, lung and liver cancer. Starting in 2009, clinical trials will be conducted jointly with Kyodo University's Research Reactor Institute. (Click here for more - Japanese language